ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-259-1970
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees48
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. During the same quarter last year, the company posted ($0.12) earnings per share. View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
4 equities research analysts have issued 12-month target prices for ZIOPHARM Oncology's shares. Their predictions range from $5.50 to $7.50. On average, they expect ZIOPHARM Oncology's share price to reach $6.6250 in the next year. This suggests a possible upside of 26.7% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (8/16/2019)
- 2. HC Wainwright analysts commented, "We have updated our model to reflect the reported 1Q19 financial results, and we project revenues of $3.2M and a net loss of $0.33 per share for 2019. The company reported cash and cash equivalents of $51.5M at the end of 1Q19, which we believe is sufficient to maintain operations until 2Q20. Clinical updates on controlled IL-12 at ASCO. Management announced that two clinical updates on its controlled IL-12 program (Ad-RTS-hIL-12 plus veledimex) for the treatment of recurrent GBM (rGBM) are expected to be presented at the 2019 Oncology (ASCO) Annual Meeting in June. Recall, Ziopharm is conducting two Phase 1 studies to evaluate the IL-12 platform as a monotherapy or as combination therapy with nivolumab (marketed by Bristol-Myers Squibb (BMY; not rated) as Opdivo)." (5/9/2019)
Has ZIOPHARM Oncology been receiving favorable news coverage?
Media headlines about ZIOP stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ZIOPHARM Oncology earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for ZIOPHARM Oncology.
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 43,634,300 shares, a decrease of 7.7% from the June 30th total of 47,284,300 shares. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is presently 21.9 days. Currently, 28.3% of the company's shares are sold short. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Evotec (EVTCY), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), The Medicines (MDCO), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Genmab A/S (GMAB), Amicus Therapeutics (FOLD), Agios Pharmaceuticals (AGIO), Myokardia (MYOK) and Xencor (XNCR).
What other stocks do shareholders of ZIOPHARM Oncology own?
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
- Dr. David M. Mauney M.D., Pres (Age 50)
- Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
- Mr. David Connolly, VP of Corp. Communications & Investor Relations
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.23%), Vanguard Group Inc. (6.92%), Northern Trust Corp (1.06%), Morgan Stanley (0.85%), Charles Schwab Investment Management Inc. (0.56%) and Nuveen Asset Management LLC (0.43%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which major investors are selling ZIOPHARM Oncology stock?
ZIOP stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Ibex Investors LLC, Virtus ETF Advisers LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., HighTower Advisors LLC, BNP Paribas Arbitrage SA, UBS Asset Management Americas Inc. and Oppenheimer & Co. Inc.. View Insider Buying and Selling for ZIOPHARM Oncology.
Which major investors are buying ZIOPHARM Oncology stock?
ZIOP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Nuveen Asset Management LLC, Invesco Ltd., SG Americas Securities LLC, D. E. Shaw & Co. Inc., Renaissance Technologies LLC and Morgan Stanley. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $5.23.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $850.14 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology.
What is ZIOPHARM Oncology's official website?
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
